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Abstract 
Grade IV astrocytoma is a primary brain tumor with a high mortality rate. The survival time for astrocytoma 
grade IV is about 6-12 months. Conventional therapies that exist to date in the form of surgery, radiation and 
chemotherapy. The main problem with malignant astrocytoma is that tumor cells grow infiltratively into the 
surrounding brain tissue and are always recurrent despite conventional therapy. This condition results from a 
complex gliomagenesis process involving the role of neural cancer stem cells (NCSC). The lack of an efficient 
immune response and the micro-invasive nature of malignant astrocytoma cells has been explained by many 
immune surveillance mechanisms in brain malignancies. The survival ability of these tumors results in a 
complex interaction between the tumor and the body's immune system. The aim of this study was to evaluate the 
survival time of malignant astrocytoma grade IV  patients treated with surgery, radiotherapy with or without 
chemotherapy. A retrospective study of the survival time of patients with malignant astrocytoma grade IV 
treated by us during the period 2005 - 2015 was 12 patients. All patients postoperative craniotomy resection of 
tumors undergoing radiation with 42 Gay. Among these 6 patients received chemotherapy as well. Sexually 
male proportion more than female with ratio 1.6 : 1. Most were over 50 years old (83%), 2 patients under the 
age of 50 years. Four patients (33%) survived for one year, survived for two years found 5 patients (41%), 
survived more than 3 years 3 patients (25%) and none survived more than 5 years .. This syudy suggests that 
chemotherapy have no effect on the survival time of the patient. 
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1. Introduction 
Highly malignant astrocytoma  or high grade astrocytoma are tumors of  the central nervous system (CNS). 
They are solid tumours arising from transformed cells of the brain and/or the spinal cord. Since they directly 
originate from the CNS , they are also call primary CNS tumours.  High grade astrocytoma is term 
encompassing various histologically defined brain tumors linked by glial origin. Until recently, standard 
treatment consisted of maximum safe surgical debulking followed by external beam radiotherapy. 
chemotheraphy with temozolamide has also become for newly–presenting patients [1,4,6,11]. Prognosis remain 
extremely poor, with median a median survival of 14.6 months. Commonly radiotherapy starts 2 – 4 weeks pos- 
operatively but the optimum timing is not known. The length of life and its quality are the basic parameters 
through which one can determine the outcome . Observing this aspect high grade astrocytoma represent 
strikingly important neurosurgical and oncological problem. New diagnostic methods as well as the 
microsurgical technique in several studies did not significantly improve the survival rate, and 5 – year survival 
is still sporadic [1,3,7,10]. The objective of this study is to analyse the survival time of patients with malignant 
astrocytoma grade IV operatively treated, radiotherapy with/without chemoteraphy , to discuss factors which 
influence the survival . 
2. Patient and Methods 
Patient were identified from medical report at Bhayangkara Hospital and Siloam Hospital Surabaya. Any 
equivocal histopathology reports were reviewed by pathologist to confirm a diagnosis of WHO grade IV 
astrocytoma. 
3. Result . 
Twelve patients malignant astrocytoma grade IV wich operated on in ten years periode (2005 – 2015) the 
survival time was evaluated. All patients were treated postoperatively by radiation 42 Gay, according to 
oncological protocol, while a small number of patients was also treated by chemotherapy with temozolamide.  
Time to radiotherapy after surgery varied from two weeks to over 8 weeks. 
Table 1: Survival time of postoperative 4th grade Astroctoma patients   with radiation therapy + chemotherapy 
and without chemotherapy 
Variable Survival Time (mounth) P 
 Min - Max Mean ± SD 
Age (Years) ≤60 years (n=4) 23 – 38 33.0 ±  6.9 .023* 
>60 years (n=8) 11 – 40 17.6 ± 10.2 
Gender Male (n=7) 11-  40 20.9 ± 11.9 .533** 
Female (n=5) 13 - 38 25.4 ± 12.3 
Chemotherapy Yes (n=5) 11 - 37 23.6 ± 11.8 .432** 
No (n=7) 12 -  40 22.1 ± 12.5 
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*independent t test  ** MannWhitney test 
Table2: The difference of survival time of postoperative malignant astrocytoma grade IV  patient based on 
chemotherapy and patient age 
Age Chemotherapy Survival Time ( mounth P 
 
Min - Max Mean ± SD 
≤60 Years Yes (n=3 23 – 37 31.3 ±  7.4 .500** 
No(n=1) 38 – 38 38.0 
≤60 Years Yes(n=2 11 – 13 12.0 ±  1.4 .286** 
No(n=6 12 – 40 19.5 ± 11.36 
** MannWhitney test 
 
The summary of the results of the analysis in Table 1 showed that no survival difference was observed although 
there was a tendency for survival time in female  (25.4 months) to be longer than male  (20.9 months) and no 
significant difference (p> 0.05) between those who underwent chemotherapy and those who did not, although 
the mean survival time in those undergoing chemotherapy (23.6 months) was longer than that for no 
chemotherapy (22.1 months), indicating that the chemotherapy action was not proven to prolong survival time 
for patients with malignant astrositoma grade IV ,  
While the survival time of patients were actually affected by age. A younger patient (≤60 years) had a mean 
survival time (33.0) longer than the elderly (> 60 years) .This means the age of potentially confounding patients 
chemotherapy. To ensure this is done by certifying the sample by age group, then analyzed a chemotherapy 
effect in each age group. The results can be seen in table 2. 
Summary of chemotherapeutic effect analysis results through comparison of survival time between 
chemotherapy and no chemotherapy in each age group showed no significant difference (p> 0.005), even the 
average survival time of astrocytoma patients was longer in the non-chemotherapy group (38.0 months) than 
those who received chemotherapy (31.3 months) for age group ≤60 years and similarly for age group> 60 years, 
mean of non-chemotherapy survival time (19.5 months) than chemotherapy (12.0 months). This suggests that 
chemotherapy have no effect on the survival time of the patient. 
4. Discussion  
If high-grade astrocytoma has been diagnosed, treatment should be started as soon as possible. The most 
effective treatment high-grade astrocytoma is a combination of neurosurgery, radiotherapy, and chemotherapy 
[2,5,11]. Among these treatment modalities, neurosurgery is of highest impact, since the extent of tumour 
removal significantly determines the further course of the disease. The more radical the tumour can be resected, 
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the higher are the chances of survival [1,5]. 
Debulking surgery is beneficial in reducing the tumour load and thus the side effects of raised intracranial 
pressure and providing a more representative histological sample. Whether it provides an improvement in 
survival is controversial [7]. Retrospective studies have suggested that gross total resection as defined by post 
operative MRI findings of more than 98% tumour resection,has shown better quality of life and progression free 
survival.  The problem with gross total resection remains balancing maximal resection against potential 
neurological deficits [5]. 
Radiotherapy has been the mainstay of adjuvant therapy for high grade astrocytoma since multiple studies from 
the 1970s showed a survival benefit. However, attempts to improve on the initial benefits by increasing dosage 
of radiation has failed to have any success. Unfortunately the therapeutic window for radiotherapy to the brain is 
narrow and there is an increased incidence of radiation necrosis with increased radiation dose [2,4]. Part of the 
reason for this is the inability of conventional imaging to identify infiltrating tumour. As a result radiotherapy 
planning outlines the obvious tumour as the Gross Tumour Volume (GTV). A 2.5cm margin is then applied to 
form the Clinical Target Volume (CTV). A 0.5cm margin is added to account for set up errors and patient 
movement to form the Planning Target Volume (PTV). In other words, a 3cm margin is applied around the 
tumour that will contain normal brain.To reduce the risk of radiation necrosis the dose is therefore limited  [7]. 
The introduction of temozolomide has provided some improvement in survival. It is given orally over five 
consecutive days within a 28 day cycle. Leucopenia and thrombocytopenia are commonly associated side 
effects of this treatment. The combination of radical radiotherapy and daily, concomitant temozolomide 
followed by six cycles of adjuvant temozolomide has significantly altered the prognosis of astrocytoma grade 
IV. (3,4,5,8) 
Although the current standard treatment for high grade astrocytoma are maximal resection followed by 
radiotherapy with concomitant and adjuvant concomitant chemotherapy including temozolamide [3,5,6], median 
survival of high grade astrocytoma only <2 years and 2.5 years, respectively [6,7 ]. 
The insignificant effect of chemotherapy on survival time in my study was probably due to: 1/ small number of 
patients (n = 12). 2/ Karnofsky Performance Scores were not evaluated. 3/ no evaluation of gross / non gross 
total resection of the tumor mass. 4/ initial neurological status are not the same. 5/ time to radiotherapy, 6/ time 
to introduce chemotherapy, 7/ possibility of comorbidities that are not included in the evaluation. 8/ not all 
MGMT tests are performed. 
5. Conclusion 
This study suggests that chemotherapy have no effect on the survival time of the patient. 
6. Recommendations 
Further research is needed with large sample, more stringent inclusion and exclusion criteria and include other 
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variables such as Karnofsky Score, initial neurologic status, gross/non gross total resection , and other comorbid 
diseases. 
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